The RP2D of 115 mg/m2 daily in patients <18 years of age was about twice the regulatory-approved adult NSCLC starting dose, as predicted by pre-clinical studies of neuroblastoma harboring ALK mutations25. The gene discussed is ALK; the disease is neuroblastoma.